We tested the hypothesis that observationally and genetically increased YKL-40 concentrations are associated with alcoholic liver and pancreas damage and disease.
YKL-40 denotes a 40-kDa plasma protein with the 3 N-terminal amino acids being Y (tyrosine), K (lysine), and L (leucine). Plasma YKL-40 regulates vascular endothelial growth factor and plays a role in angiogenesis, inflammation, and extracellular tissue remodeling (1, 2 ) and, consequently, is increased in patients with diseases characterized by inflammation, tissue remodeling, and fibrosis (3 ). In case-control studies with 24 to 607 participants, plasma YKL-40 was increased in patients with alcoholic liver disease (4 -6 ) and chronic pancreatitis (7 ) . However, such observational findings are potentially prone to selection bias, confounding, and reverse causation. It is therefore unknown whether increased plasma YKL-40 is a marker and/or a cause of alcoholic liver and pancreas damage and disease. These possibilities can be addressed respectively in a cohort study of the general population and in a mendelian randomization study. The latter design uses genetic variants associated with lifelong increased plasma YKL-40 concentrations that are largely unconfounded and not prone to reverse causation (8, 9 ) . Indeed, plasma concentrations of YKL-40 are partly heritable (10 ) and the rs4950928, a single nucleotide polymorphism in the proximal promoter of CHI3L1, accounts for 9% of its variance (10 ) . Mechanistically, MYC/ MAX transcriptional factors do not bind well to the minor allele of rs4950928 (11 ) , which decreases CHI3L1 transcription (12 ) and consequently plasma YKL-40 concentrations (13) (14) (15) .
We tested the hypothesis that observationally and genetically increased plasma YKL-40 concentrations are associated with alcoholic liver and pancreas damage and disease. For this purpose, we performed cohort and mendelian randomization studies in 86 258 individuals from the Danish general population, with measured plasma YKL-40 concentrations (n ϭ 21 646) and CHI3L1 rs4950928 genotype (n ϭ 84 738). First, in the cohort study, we examined association between increased plasma YKL-40 concentrations and alcoholic liver and pancreas damage and disease. Second, in the mendelian randomization study, we examined whether CHI3L1 rs4950928 genotype is associated with plasma YKL-40 concentrations and with alcoholic liver and pancreas damage and disease. Third, in cohort and mendelian randomization studies combined, we compared the association of observationally and genetically increased YKL-40 concentrations with risk of alcoholic liver and pancreas damage and disease. Finally, we estimated the absolute 10-year risk of alcoholic liver cirrhosis as a function of combined increased plasma YKL-40 concentrations and excessive alcohol intake. Among our participants, only about 9% reported not drinking alcohol (a combination of people who stopped drinking and lifetime abstainers) (see Supplemental Table 1 , which accompanies the online version of this article at http://www.clinchem.org/content/ vol60/issue11), and we therefore included all participants in all analyses.
Methods

PARTICIPANTS
We used 2 independent prospective studies with individuals selected to reflect the adult Danish population aged 20 years and older, the Copenhagen City Heart Study (CCHS) 7 (16 ) and the Copenhagen General Population Study (CGPS) (17) (18) (19) . All participants were whites of Danish descent, and there was no overlap between the 2 studies. Before examination in both studies, participants filled out a self-administered questionnaire which was completed together with an investigator on the day of attendance, where a physical examination was performed and blood was drawn for immediate biochemical analyses, as well as for storage at Ϫ80°C for later DNA and biochemical analyses.
THE CCHS STUDY
We used the 1991-1994 examination of the CCHS. Of 9601 participants, 8773 were genotyped for rs4950928. Plasma YKL-40 concentrations were measured in samples frozen for 12-15 years at Ϫ80°C in 8444 of these participants (20 ) .
THE CGPS STUDY
CGPS was initiated in 2003 with ongoing enrollment. Of the first 76 657 participants, 75 965 were genotyped for rs4950928. Plasma YKL-40 concentrations were measured in fresh samples in 3211 participants and in samples frozen for 7 years at Ϫ80°C in 9991 participants. 
ENDPOINTS
Diagnoses of diseases listed in online Supplemental
ETHICS
The study was approved by Herlev Hospital and a Danish scientific ethics committee (nos. 100.2039/91 and 01-144/01) and was conducted according to the Declaration of Helsinki. Participants gave written informed consent.
PLASMA YKL-40 CONCENTRATIONS
Plasma YKL-40 concentrations were determined in duplicate by use of a 2-site, sandwich-type ELISA (Quidel Corp.), with streptavidin-coated microplate wells, a biotinylated-Fab monoclonal capture antibody, and an alkaline phosphatase-labeled polyclonal detection antibody. The recovery of the ELISA was 102%, and the detection limit was 10 g/L. The intraassay CVs were 5% at 40 g/L and 4% at 104 g/L and 155 g/L. The interassay CV was Ͻ6%.
We stratified plasma YKL-40 concentrations into 5 percentile categories to evaluate both tertiles in the lower range and extreme phenotypes in the upper range; the latter was a priori presumed to infer increased risk and was identical to previous reports (21, 22 ) : 0%-33%, 34%-66%, 67%-90%, 91%-95%, and 96%-100%. Because plasma YKL-40 increases with increasing age, YKL-40 percentile categories al-lowed for age differences (see online Supplemental Fig.  1 ). For the absolute 10-year risk of alcoholic liver cirrhosis, the YKL-40 percentile was calculated as a function of age in years and plasma YKL-40 in g/L with the following equation (23 ) 
MARKERS OF POSSIBLE LIVER AND PANCREAS DAMAGE
We used alanine aminotransferase; alkaline phosphatase; albumin; erythrocyte mean corpuscular volume; bilirubin; ␥-glutamyl transpeptidase; coagulation factors II, VII, and X; pancreatic amylase; C-reactive protein (CRP); and fibrinogen as markers of possible liver and pancreas damage. These were measured by use of standard hospital assays subjected to a daily internal quality control assessing assay precision and a monthly external quality control assessing assay accuracy. Erythrocyte mean corpuscular volume and coagulation factors II, VII, and X were measured only in the participants from the CGPS. For the CCHS, samples frozen for 12-15 years were used for analyses, except for albumin, which was measured on fresh samples. For the CGPS, fresh blood samples were used for analyses.
COVARIATES
Participants reported on present and past smoking habits and weekly alcohol consumption in the questionnaire. We subdivided participants into neverand ever-smokers, the latter category including both previous and current smokers. For ever-smokers, a pack-year was defined as 20 g tobacco smoked per day for 1 year. School education was reported as number of years of basic schooling and divided into three groups: up to 7 years, 8 -10 years, and 11 or more years. Body mass index was calculated as measured weight in kilograms divided by measured height in meters squared.
GENOTYPING
We genotyped rs4950928 in 84 738 participants with DNA available for genotyping (Ͼ99.9% were genotyped due to reruns). Genotyping was performed by use of TaqMan (Applied Biosystems by Life Technologies Corp.) assays. We used a forward (AGTTCCCA TAAAAGGGCTGGTTT) and a reverse (CCCAGGC CCTGTACTTCCTTTATAT) primer for the PCR amplification and a common (CTCCCCCACGCGGC) and a variant (ACTCCCCGACGCGGC) probe to determine genotype.
STATISTICAL ANALYSIS
We used STATA version 12. Trend tests were performed by use of Cuzick nonparametric test for trend. General linear models calculated r 2 values. HardyWeinberg equilibrium was investigated by use of a 2 test. We performed no corrections for multiple comparisons.
Risk estimates and corresponding 95% confidence intervals for alcoholic liver and pancreas disease were computed as hazard ratios (HRs) by use of Cox regression analysis. The multifactorially adjusted model included adjustments for age, sex, ever smoking (yes/no), cumulative smoking (packyears), alcohol consumption (number of drinks per week, 1 drink Ϸ 12 g alcohol), body mass index (kg/ m 2 ), education (Յ7, 8 -10, Ն11 years of schooling), and study population (CCHS or CGPS). We assessed the assumption of proportional hazards graphically by plotting -ln (survival probability) against ln (analysis time) as well as by using Schoenfeld residuals, and did not detect any major violations of the proportional hazard assumption. Participants with events before blood sampling were excluded from analyses of plasma YKL-40 concentrations, i.e., we used left truncation (delayed entry), meaning that participants only entered into the Cox model at their age at examination in 1991-1994 or 2003-2010, when blood for plasma YKL-40 measurement was drawn. Recurrent events were not considered.
In the mendelian randomization study for analyses of rs4950928 genotype, we did not exclude participants, because genotype is constant throughout life, and participants were considered at risk from the day of birth. Otherwise, analyses were like those described above for the cohort study.
For cohort and mendelian randomization studies combined, observational HRs and genetic odds ratios (ORs) for a doubling in YKL-40 concentrations on a continuous scale were assessed by calculating these ratios for an increase of 1 unit of base 2 logarithm of plasma YKL-40; in individuals without a YKL-40 measurement and for genetically increased concentrations, the well-known association between genotype and YKL-40 concentrations in other participants were applied, taking age, sex, and study population into account. We chose a doubling in YKL-40 concentration as an outcome, as we have done previously (20 ) , because this allows for a simple interpretation of results. Furthermore, YKL-40 increased exponentially with increasing age, and CHI3L1 rs4950928 single nucleotide polymorphism was responsible for a genetically doubling or tripling in plasma YKL-40 concentrations.
In the instrumental variable analyses, we used a 2-stage least squares regression, where rs4950928 genotype examines the effect of a genetically doubling in plasma YKL-40 on the concentration of markers of possible liver and pancreas damage. The first stage of the 2-stage least squares estimator is a linear regression of rs4950928 genotype on plasma YKL-40, which generates predicted values for plasma YKL-40. The second stage is a linear regression of outcome on predicted plasma YKL-40 concentrations. To estimate the effect of a genetic doubling in plasma YKL-40 on alcoholic liver and pancreas disease, we used a control function estimator with a logistic regression at second stage. The control function estimator follows the same principle as the 2-stage estimator, but additionally includes the estimated residuals from the first stage regression. These residuals may be correlated to unmeasured confounders, in which case they will help to control the effect of unmeasured confounders on outcome. The strength of rs4950928 as instrument was assessed from the first-stage regression, where an F statistic Ͼ10 usually indicates sufficient statistical strength (8 ) . An r 2 value expressed as a percentage was used as a measure of the contribution of rs4950928 genotype to the variation in plasma YKL-40 concentrations.
Absolute risks of alcoholic liver cirrhosis by plasma YKL-40 percentile groups; smoking (never-smokers/ ever-smokers); or sex (woman/man), age (Ͻ50, 50 -70, Ͼ70 years), and alcohol consumption (Յ7, 7-20, Ͼ20 drinks per week) were estimated by using the regression coefficients from a Poisson regression; we examined alcoholic liver cirrhosis, as it was the endpoint associated most strongly with plasma YKL-40 concentrations. Absolute risks are presented as estimated incidence rates (events per 10 years) in percentages.
Results
The combined studies included 86 258 individuals from the Danish general population, of whom 84 738 were genotyped and 21 646 had plasma YKL-40 concentrations measured; we only show combined results, as the results for the 2 studies separately were similar. From 1976 through 2011, with information on all participants, 226 individuals developed alcoholic liver cirrhosis, 836 any alcoholic liver disease, 378 alcoholic pancreatitis, and 730 any pancreatitis (see online Supplemental Table 2 ). CHI3L1 rs4950928 genotypes were in Hardy-Weinberg equilibrium (P ϭ 0.37), with a minor allele frequency of 21%. Baseline characteristics as a function of YKL-40 percentile categories, alcoholic liver and pancreas disease, and rs4950928 genotype are shown in Table 1 and online Supplemental Tables 2-4 . Collectively, these data illustrate that YKL-40 concentrations and alcoholic liver and pancreas disease are strongly associated with many covariates and potential confounders, whereas genotype is associated with none, and therefore can be used as a largely unconfounded instrument to study the importance of lifelong increased YKL-40 concentrations not prone to reverse causation.
PLASMA YKL-40 CONCENTRATION AND ALCOHOLIC LIVER AND PANCREAS DAMAGE AND DISEASE: COHORT STUDY
The higher percentiles of plasma YKL-40 were associated with markers of possible liver and pancreas damage, that is, with increased concentrations of alanine aminotransferase, bilirubin, alkaline phosphatase, ␥-glutamyl transferase, erythrocyte mean corpuscular volume, CRP, and fibrinogen and with decreased concentrations of albumin; coagulation factors II, VII, and X; and pancreatic amylase ( Fig. 1 and online Supplemental Fig. 2 ). For some markers, this was most pronounced in the upper 10 percentiles of plasma YKL-40 concentrations.
Risk of all disease endpoints increased with increased plasma YKL-40 percentile category, and was particularly high for individuals in the 96%-100% plasma YKL-40 percentile category (Fig. 2) . The multifactorially adjusted HR for alcoholic liver cirrhosis was 41 (95% CI, 14 -118) for the 96%-100% vs 0%-33% YKL-40 percentile category. Corresponding HRs were 7.9 (5.1-12) for any alcoholic liver disease, 4.1 (1.7-10) for alcoholic pancreatitis, and 3.4 (1.9 -6.1) for any pancreatitis.
CHI3L1 RS4950928 GENOTYPE, PLASMA YKL-40 CONCENTRATION, AND ALCOHOLIC LIVER AND PANCREAS DAMAGE AND DISEASE: MENDELIAN RANDOMIZATION STUDY
There was a doubling (99% increase) in geometric mean of plasma YKL-40 concentrations from CC (4.4% of all individuals) to GC (32.9%) genotype and a tripling (196% increase) in concentrations from CC to GG (62.7%) genotype (see online Supplemental Fig. 3 ; P-trend Ͻ1 ϫ 10 Ϫ300 ); genotype explained 14% of the variation in plasma YKL-40 concentrations and the F statistic was 1690, indicating that rs4950928 is a very strong instrument to examine the effect of lifelong increased plasma YKL-40 concentrations. Geometric mean for plasma YKL-40 was 24 ng/mL for individuals with the CC genotype, 48 ng/mL for the GC genotype, and 71 ng/mL for the GG genotype. CHI3L1 rs4950928 genotype was not associated with markers of possible liver and pancreas damage (see online Supplemental Fig. 4) , or with risk of alcoholic liver cirrhosis, any alcoholic liver disease, alcoholic pancreatitis, and any pancreatitis (Fig. 3) . Table 2 ).
e ALC, alcoholic liver cirrhosis; ALP, any alcoholic liver disease; AP, alcoholic pancreatitis, P, any pancreatitis. 1-1.9) observationally and 1.1 (0.8 -1.5) genetically  for alcoholic pancreatitis, and 1.3 (1.1-1.6 ) observationally and 1.0 (0.8 -1.3) genetically for any pancreatitis (Fig. 4) .
YKL-40 and Alcoholic Liver and Pancreas
ABSOLUTE 10-YEAR RISK OF ALCOHOLIC LIVER CIRRHOSIS
Although genetically increased plasma YKL-40 concentrations were not associated with risk of alcoholic liver cirrhosis, YKL-40 might still be a useful marker of future risk of this disease. Therefore, we calculated the absolute 10-year risk of alcoholic liver cirrhosis as a function of age, smoking (or sex), alcohol consumption, and plasma YKL-40 percentile categories ( Fig. 5 ; online Supplemental Fig. 6 ). The absolute 10-year risk of alcoholic liver cirrhosis was increased in eversmokers vs never-smokers, excessive drinkers (Ͼ20 drinks/week) vs modest drinkers (Ͻ7 drinks/week), and 51-to 70-year-olds vs Ͻ50-year-olds, and the risk increased stepwise with increasing plasma YKL-40 categories (all P Ͻ 6 ϫ 10 Ϫ8 ). The risk was lower in individuals Ͼ70 years old than in individuals Ͻ50 (P ϭ 2 ϫ 10 Ϫ5 ), possibly explained by the early age of onset and low life expectancy of this disease. There was no difference (P ϭ 0.20) in risk of alcoholic liver cirrhosis in moderate (7-20 drinks/week) vs modest (Ͻ7 drinks/ week) drinkers.
Discussion
Studying 86 258 individuals from the general population, we found that increased plasma YKL-40 concentrations were associated with alcoholic liver and pancreas damage and disease, whereas genetically increased concentrations were not. These are novel findings.
Our results that rs4950928 genotype is not associated with risk of alcoholic liver disease are in conflict with an earlier report on the development of liver fibrosis in 440 patients with hepatitis C (13 ), but are supported by a later report from the larger HALT-C study of patients with chronic hepatitis C infection (24 ) . One explanation for this discrepancy could be that the rs4950928 genotype is more important in early rather than late and more advanced liver fibrosis. Thus, more studies are needed to explore the role of this polymorphism in patients with chronic hepatitis C infection.
Although our study does not support the hypothesis that lifelong increased plasma YKL-40 is a cause of alcoholic liver and pancreas disease, it is still possible that YKL-40 concentrations are associated with degree Individuals with event before blood sampling were excluded from analyses of the total of 21646 participants with measured plasma YKL-40 concentrations; therefore, the numbers of participants varies between studies of the different disease endpoints. Multifactorially adjusted model included adjustments for age, sex, alcohol consumption, smoking, body mass index, education, and study population.
YKL-40 and Alcoholic Liver and Pancreas Disease
Clinical Chemistry 60:11 (2014) 1435 Fig. 3 . HRs of alcoholic liver and pancreas disease according to CHI3L1 rs4950928 genotype. The rare homozygote (CC) is the reference group. Individuals with event before blood sampling were not excluded from analyses of the total of 84738 genotyped participants. The multifactorially adjusted model included adjustments for age, sex, alcohol consumption, smoking, body mass index, education, and study population. ⌬YKL-40 indicates the genotype-associated difference in YKL-40 concentration from that of the CC genotype.
of liver fibrosis and prognosis in patients with alcoholic liver disease (4, 6 ) . Thus, YKL-40 could be a prognostic marker that plays a role in alcoholic liver disease progression after diagnosis, and that, potentially, inhibition of YKL-40 activity might be used in treatment of alcoholic liver disease. However, the design of the study was not adequate to investigate noninvasive fibrosis markers, and it is also possible that the higher YKL-40 concentrations observed among individuals who subsequently developed alcoholic liver cirrhosis were indicative of established fibrosis in a prediagnostic stage. Even in this case, measurement of plasma YKL-40 in alcoholic patients might be a potential alternative to invasive liver biopsy in identifying individuals at very high risk of alcoholic liver cirrhosis, thereby possibly improving treatment and compliance to alcohol reduction in these patients. Although such a potential use of plasma YKL-40 measurement needs to be tested directly in other studies, it has the potential to lower costs, patient morbidity, and liver sampling errors.
Alcoholic liver cirrhosis is by definition caused by excessive alcohol consumption, regardless of plasma YKL-40 concentrations. Indeed, there was no difference in risk of alcoholic liver cirrhosis between partici- The multifactorially adjusted model included adjustment for age, sex, alcohol consumption, smoking, body mass index, education, and study population. YKL-40 percentile was calculated as a function of age in years and plasma YKL-40 in g/L: YKL-40 percentile ϭ 100/(1 ϩ YKL-40 Ϫ3 ϫ 1.062 age ϫ 5000). Percentile categories were stratified by age (Ͻ50, 50 -70, Ͼ70 years), smoking (never, ever), and alcohol consumption (Ͻ7, 7-20, Ͼ20 weekly drinks).
pants drinking Ͻ7 vs 7-20 drinks/week. However, the risk of alcoholic liver cirrhosis was increased among participants with plasma YKL-40 concentrations within the top 5% who drank Ͻ7 drinks/week. Possibly this can be explained by the fact that the absolute risk was estimated by using the regression coefficients from Poisson regression, which assumes that risk increases multiplicatively with each increase in plasma YKL-40 percentile category regardless of smoking, sex, age, and alcohol consumption.
The threshold of alcohol consumption needed to develop alcoholic liver disease varies: although some moderate drinkers do develop alcoholic liver disease, not all heavy drinkers do. Alcohol consumption in this study was self reported at baseline, we did not have information on lifetime abstainers, and some heavy drinkers might have underreported their alcohol consumption. Indeed, half of the participants who developed any alcoholic liver disease after the initiation of the study had reported a weekly alcohol consumption of 10 drinks or less at baseline; thus we included all the participants in the analyses regardless of alcohol consumption.
It may seem surprising that increased YKL-40 concentrations were inversely associated with pancreatic amylase and directly associated with risk of pancreatitis. Although acute pancreatitis is associated with increased concentrations of pancreatic amylase, chronic pancreatitis is not, and it may even be associated with decreased concentrations of pancreatic amylase. This might explain the fact that increased plasma YKL-40 was associated with decreasing concentrations of pancreatic amylase as well as with increased risk of pancreatitis.
Limitations of this study include survival bias and selective nonresponse to the invitation owing to individuals being very sick with liver and/or pancreatic disease. Both of these concerns would likely lead to underrepresentation of these individuals in our sample of the general population and thereby bias the results toward the null hypothesis. Therefore, these limitations cannot explain our findings for alcoholic liver disease and pancreatitis. Second, the diagnoses were ascertained from the hospital system, and not from a dedicated clinic with the specific intent of studying these diseases. It is possible that some of the healthy controls might have had the diagnosis, had they been examined more thoroughly, which might have significantly influenced the results. Taken together, considering the presumed survival bias, selective noncompliance, and false-negative controls, our significant risk estimates of liver and pancreatic diseases are probably rather conservative and the true risks might be even higher. Our negative results regarding rs4950928 are likely accurate, since the distribution of genotypes does not deviate from Hardy-Weinberg equilibrium. Third, our study was based on fresh samples as well as samples frozen for 7-15 years at Ϫ80°C. Because plasma YKL-40 remains stable regardless of repetitive thawing and freezing (25 ) , and because internal controls in our laboratory have demonstrated that plasma YKL-40 is stable for at least 16 years when stored at Ϫ80°C, we do not believe that YKL-40 measurement in frozen samples has distorted our analyses to a large degree. Finally, we only studied white individuals of Danish descent, and our results are therefore not necessarily directly applicable to other ethnic groups; however, we are not aware of data to suggest that the present results should not be applicable to most ethnic groups.
In conclusion, in this large study of individuals from the general population, we found that a plasma YKL-40 concentration within the top 5% was a marker of alcoholic liver cirrhosis, but found no evidence to support a causal relationship.
